Jaya Sangodkar, Ph.D. - Publications

2012 Cancer Biology Icahn School of Medicine at Mount Sinai, New York, NY, United States 
Molecular Biology, Cell Biology, Genetics, Oncology

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Taylor SE, O'Connor CM, Wang Z, Shen G, Song H, Leonard D, Sangodkar J, LaVasseur C, Avril S, Waggoner S, Zanotti K, Armstrong AJ, Nagel C, Resnick K, Singh S, et al. The highly recurrent PP2A Aα-subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis. Cancer Research. PMID 31142515 DOI: 10.1158/0008-5472.CAN-19-0218  0.76
2019 Tohmé R, Izadmehr S, Gandhe S, Tabaro G, Vallabhaneni S, Thomas A, Vasireddi N, Dhawan NS, Ma'ayan A, Sharma N, Galsky MD, Ohlmeyer M, Sangodkar J, Narla G. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma. Jci Insight. 4. PMID 30830869 DOI: 10.1172/jci.insight.125693  0.76
2019 Mazhar S, Taylor SE, Sangodkar J, Narla G. Targeting PP2A in cancer: Combination therapies. Biochimica Et Biophysica Acta. Molecular Cell Research. 1866: 51-63. PMID 30401535 DOI: 10.1016/j.bbamcr.2018.08.020  0.76
2018 Noto FK, Adjan Steffey V, Tong M, Ravichandran K, Zhang W, Arey A, McClain CB, Ostertag E, Mazhar S, Sangodkar J, Difeo A, Crawford J, Narla G, Jamling TY. Sprague Dawley Rag2 null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts. Molecular Cancer Therapeutics. PMID 30206106 DOI: 10.1158/1535-7163.MCT-18-0156  0.76
2018 Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, et al. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Science Translational Medicine. 10. PMID 30021885 DOI: 10.1126/scitranslmed.aaq1093  0.76
2018 Narla G, Sangodkar J, Ryder CB. The impact of phosphatases on proliferative and survival signaling in cancer. Cellular and Molecular Life Sciences : Cmls. PMID 29725697 DOI: 10.1007/s00018-018-2826-8  0.76
2018 McClinch K, A Avelar R, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, et al. Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer. Cancer Research. PMID 29358171 DOI: 10.1158/0008-5472.CAN-17-0123  0.76
2017 O'Connor CM, Perl A, Leonard D, Sangodkar J, Narla G. Therapeutic Targeting of PP2A. The International Journal of Biochemistry & Cell Biology. PMID 29107183 DOI: 10.1016/j.biocel.2017.10.008  0.76
2017 Wiredja DD, Ayati M, Mazhar S, Sangodkar J, Maxwell S, Schlatzer D, Narla G, Koyutürk M, Chance MR. Phosphoproteomics Profiling of Non-Small Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator. Proteomics. PMID 28961369 DOI: 10.1002/pmic.201700214  0.76
2017 Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, et al. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. The Journal of Clinical Investigation. PMID 28504649 DOI: 10.1172/JCI89548  0.76
2015 Kastrinsky DB, Sangodkar J, Zaware N, McClinch K, Farrington CC, Giannini HM, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M. Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534]. Bioorganic & Medicinal Chemistry. 23: 7487. PMID 28290285 DOI: 10.1016/j.bmc.2015.11.002  0.76
2015 Sangodkar J, Farrington C, McClinch K, Galsky MD, Kastrinsky DB, Narla G. All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase. The Febs Journal. PMID 26507691 DOI: 10.1111/febs.13573  0.76
2015 Kastrinsky DB, Sangodkar J, Zaware N, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M. Reengineered tricyclic anti-cancer agents. Bioorganic & Medicinal Chemistry. 23: 6528-34. PMID 26372073 DOI: 10.1016/j.bmc.2015.07.007  0.76
2014 Yuen T, Stachnik A, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr S, Sangodkar J, Bailey J, et al. Bisphosphonates inactivate human EGFRs to exert antitumor actions. Proceedings of the National Academy of Sciences of the United States of America. 111: 17989-94. PMID 25453081 DOI: 10.1073/pnas.1421410111  0.32
2014 Stachnik A, Yuen T, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr S, Sangodkar J, Scherer T, et al. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: 17995-8000. PMID 25453078 DOI: 10.1073/pnas.1421422111  0.32
2013 Das TK, Sangodkar J, Negre N, Narla G, Cagan RL. Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors. Oncogene. 32: 3184-97. PMID 22890320 DOI: 10.1038/onc.2012.326  0.32
2012 Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, et al. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. The Journal of Clinical Investigation. 122: 2637-51. PMID 22653055 DOI: 10.1172/JCI62058  0.32
2010 Sangodkar J, Katz S, Melville H, Narla G. Lung adenocarcinoma: lessons in translation from bench to bedside. The Mount Sinai Journal of Medicine, New York. 77: 597-605. PMID 21105123 DOI: 10.1002/msj.20226  0.76
2009 Difeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G, Martignetti JA. KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. Cancer Research. 69: 4733-41. PMID 19435908 DOI: 10.1158/0008-5472.CAN-08-4282  0.32
2009 Sangodkar J, DiFeo A, Feld L, Bromberg R, Schwartz R, Huang F, Terzo EA, Choudhri A, Narla G. Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. Lung Cancer (Amsterdam, Netherlands). 66: 292-7. PMID 19328586 DOI: 10.1016/j.lungcan.2009.02.014  0.76
2009 Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, Choudhri A, McClinch K, Hatami R, Scheer E, Kremer-Tal S, Martignetti JA, Hui A, Leung WK, Friedman SL, Narla G. Functional role of the KLF6 tumour suppressor gene in gastric cancer. European Journal of Cancer (Oxford, England : 1990). 45: 666-76. PMID 19101139 DOI: 10.1016/j.ejca.2008.11.009  0.76
2008 Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. The Journal of Clinical Investigation. 118: 2711-21. PMID 18596922 DOI: 10.1172/JCI34780  0.32
Show low-probability matches.